Skip to content
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter
Main Menu
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter

About Me

Nick Mars - Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis. Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Social Icons

Facebook1,750FansLikeX (Twitter)759FollowersFollowInstagram2,500FollowersFollowPinterest1,365FollowersPinYoutube2,700SubscribersSubscribeTiktok2,900FollowersFollowTelegram2,000MembersJoinSoundcloud1,963FollowersFollowVimeo1,254FollowersFollowDribbble3,520FollowersFollow
  • Support
    • Documentation
    • Documentation
    • Video Tutorials
    • Video Tutorials
    • Support Forums
    • Support
  • Support
  • About Theme
  • About theme
  • Visit Us
  • Visit Us
Wednesday, June 24, 2026
  • News
  • Regulatory

AbbVie’s Boey Approved in Canada for Glabellar Lines 

Takeaways:  Boey gives Allergan Aesthetics a&...

Arisa Smith
June 24, 2026
Read More
  • Companies
  • News
  • Public Health

Roche’s Itovebi Moves Closer to Public Access in Canada 

Takeaways:  Roche’s pCPA win for&nb...

Arisa Smith
June 24, 2026
Read More
  • News
  • R&D

Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 

Takeaways:  Zasocitinib’s Phase 3 win ov...

Arisa Smith
June 24, 2026
Read More
  • News
  • Regulatory

Health Canada approves Cysklar (cysteamine ophthalmic solution) for cystinosis-related corneal crystals 

Takeaways:   Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...

Arisa Smith
April 15, 2026
Read More
  • News
  • Regulatory

ALK Reports Health Canada Approval for Needle-Free Anaphylaxis Spray 

Takeaways:   Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among ...

Arisa Smith
April 15, 2026
Read More
  • News
  • Regulatory

Health Canada grants NOC to Saphnelo (anifrolumab) SC autoinjector for SLE 

Takeaways:  AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...

Arisa Smith
April 13, 2026
Read More
  • News
  • Regulatory

Health Canada approves Empaveli (pegcetacoplan) for C3G/IC-MPGN 

Takeaways:  Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...

Arisa Smith
April 9, 2026
Read More
  • News
  • Regulatory

Health Canada approves Denoza, a biosimilar to Prolia (denosumab) 

Takeaways:  Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...

Arisa Smith
April 7, 2026
Read More
  • News
  • Regulatory

Health Canada clears CTA for AFTX-201 in BAG3 DCM, to be evaluated in Phase 1/2 UPBEAT trial 

Takeaways:  Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...

Arisa Smith
April 6, 2026
Read More
  • Deals
  • News

WELL Health Technologies partners with AliveCor to offer cardiologist-reviewed ECG insights via Kardia app in Canada 

Takeaways:  This tie-up effectively turns WELL’s cardiologist network into an on‑demand, paid “virtual read” service layered on top of AliveCor’s at‑home ECG hardware and AI, direc...

Arisa Smith
April 2, 2026
Read More
  • News
  • Regulatory

Apotex Expands Ophthalmology Portfolio with Health Canada Approval of CLOBIVIS 

Takeaways:   CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics.  In marke...

Arisa Smith
March 25, 2026
Read More
1...8910

Social Icons

Facebook1,000FansLikeX (Twitter)1,000FollowersFollowInstagram1,000FollowersFollowPinterest1,000FollowersPinYoutube1,000SubscribersSubscribeTiktok1,000FollowersFollowTelegram1,000MembersJoinSoundcloud1,000FollowersFollowVimeo1,000FollowersFollowDribbble1,000FollowersFollow

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis.

Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Email: sample@gmail.com
Call Us: +987 95 95 64 82

Category List

  • Commercial(11)
  • Companies(13)
  • Deals(5)
  • Editor's Pick(5)
  • Latest Updates(1)
  • Manufacturing(6)
  • Must Read(4)
  • News(66)
  • Opinions(30)
  • Public Health(10)
  • R&D(12)
  • Regulatory(38)
  • Technology(8)

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Copyright © 2026 | Powered by News Magazine X